ArticleScientific reports2026
The Toll-like receptor 1/2 ligand Pam3Cys inhibits memory impairment after traumatic brain injury in male and female rats.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Amnesia is common after traumatic brain injury (TBI). Toll-like receptor 1/2 agonist, tri-palmitoyl-S-glyceryl-cysteine (Pam3Cys), prevents TBI neuroinflammation. We investigated Pam3Cys potential to ameliorate TBI amnesia, and discerned the effect between male and female. Male and female adult rats were trained in the Morris water maze (n = 160) and shuttle box (n = 80). Then, animals received mild TBI by controlled cortical impact. Twenty min after TBI, Pam3Cys was injected by intra-cerebroventricular route. Spatial memory was assessed 7 and 28 days whereas avoidance memory was evaluated 2 and 6 days after TBI. Brain damage was evaluated by TTC and Nissl staining. Rats effectively learned, with no sex difference, spatial and avoidance tasks by progressive decrease in latency and distance to platform, and avoiding shock chamber during training. One week after acquisition, memory retrieval was disrupted in naïve female rats which traveled 22% more than males to reach platform position (P < 0.01). At four weeks, sham-operated female rats spent 26% less time than males in platform position (P < 0.01). TBI significantly disrupted both spatial and avoidance memories at all measured times. Spatial memory of females showed greater impairment than males at four weeks after TBI (40% less presence in platform position, P < 0.01). No sex difference existed in avoidance memory under control or TBI. Pam3Cys reduced TBI-induced latency increase in both sexes at one week (P < 0.05, P < 0.00001), but at four weeks, only in males (P < 0.05). It also mitigated reduced presence in target quadrant in both sexes at one week (P < 0.05), and in females at four weeks (P < 0.01). Pam3Cys prevented all rats at two days, and 60% of rats at 6 days after TBI, from entering the shock chamber (P < 0.01, P < 0.001 compared to TBI group) with no sex difference. Pam3Cys reduced TBI-induced cortical damage (70% decrease, P < 0.001) and neuronal death (75% decrease, P < 0.001) in the hippocampus. In short periods after mild TBI, impairment of spatial memory and Pam3Cys preventive effect are identical in male and female rats. However, at long-term periods, both effects are prominent in female rats. Modulation of TBI neuroinflammation seems to involve in Pam3Cys effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.